In this article, we will discuss Pazopanib (Dosage Overview). So, let’s get started.
Pazopanib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
The recommended dose of Pazopanib is 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). The dose of Pazopanib should not exceed 800 mg. Do not crush tablets due to the potential for increased rate of absorption which may affect systemic exposure.If a dose is missed, it should not be taken if it is less than 12 hours until the next dose.
Dose Modification Guidelines
Initial dose reduction should be 400 mg, and additional dose decrease or increase should be in 200 mg steps based on individual tolerability. The dose of Pazopanib should not exceed 800 mg. Hepatic Impairment: The dosage of Pazopanib in patients with moderate hepatic impairment should be reduced to 200 mg per day. There are no data in patients with severe hepatic impairment; therefore, use of Pazopanib is not recommended in these patients.
Concomitant Strong CYP3A4 Inhibitors: The concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) may increase pazopanib concentrations and should be avoided. If coadministration of a strong CYP3A4 inhibitor is warranted, reduce the dose of Pazopanib to 400 mg. Further dose reductions maybe needed if adverse effects occur during therapy. This dose is predicted to adjust the pazopanib AUC to the range observed without inhibitors. However, there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inhibitors.
Concomitant Strong CYP3A4 Inducer: The concomitant use of strong CYP3A4 inducers (e.g., rifampin) may decrease pazopanib concentrations and should be avoided. pazopanib should not be used in patients who can not avoid chronic use of strong CYP3A4 inducers.